

Title (en)
SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D₃ RECEPTORS

Title (de)
SUBSTITUIERTE TETRAHYDROISOCHINOLINEDERIVATE ALS DOPAMINE D₃ REZEPTOR-MODULATOREN

Title (fr)
DERIVES DE TETRAHYDRO-ISOQUINOLINE SUBSTITUEE, UTILES EN TANT QUE MODULATEURS DES RECEPTEURS D₃ DE LA DOPAMINE

Publication
EP 0981516 A1 20000301 (EN)

Application
EP 98929278 A 19980427

Priority
• EP 9802581 W 19980427
• GB 9708694 A 19970430

Abstract (en)
[origin: WO9849145A1] Compounds of formula (I), wherein R<1> represents a substituent selected from a hydrogen or halogen atom; a hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-4alkyl, C1-4alkoxy, arylC1-4alkoxy, C1-4alkylthio, C1-4alkoxyC1-4alkyl, C3-6cycloalkylC1-4alkoxy, C1-4alkanoyl, C1-4alkoxycarbonyl, C1-4alkylsulphonyl, C1-4alkylsulphonyloxy, C1-4alkylsulphonylC1-4alkyl, arylsulphonyl, arylsulphonyloxy, arylsulphonylC1-4alkyl, C1-4alkylsulphonamido, C1-4alkylamido, C1-4alkylsulphonamidoC1-4alkyl, C1-4alkylamidoC1-4alkyl, arylsulphonamido, arylcarboxamido, arylsulphonamidoC1-4alkyl, arylcarboxamidoC1-4alkyl, aroyl, aroylC1-4alkyl, or arylC1-4alkanoyl group; a group R<3>OCO(CH₂)_p, R<3>CON(R<4>)(CH₂)_p, R<3>R<4>NCO(CH₂)_p or R<3>R<4>NSO₂(CH₂)_p where each of R<3> and R<4> independently represents a hydrogen atom or a C1-4alkyl group or R<3>R<4> forms part of a C3-6 azacycloalkane or C3-6(2-oxo)azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar<1>Z, wherein Ar<1> represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring and z represents a bond, O, S, or CH₂; R<2> represents a hydrogen atom or a C1-4alkyl group; q is 1 or 2; Ar represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system; and salts thereof. Compounds of formula (I) and their salts have affinity for dopamine receptors, in particular the D₃ receptor, and thus potential in the treatment of conditions wherein modulation of the D₃ receptor is beneficial, e.g. as antipsychotic agents.

IPC 1-7
C07D 217/04; **C07D 401/12**; **C07D 409/12**; **A61K 31/47**

IPC 8 full level
A61K 31/4725 (2006.01); **A61P 25/18** (2006.01); **A61P 43/00** (2006.01); **C07D 217/04** (2006.01); **C07D 401/12** (2006.01); **C07D 409/12** (2006.01)

CPC (source: EP)
A61P 25/18 (2017.12); **A61P 43/00** (2017.12); **C07D 217/04** (2013.01); **C07D 401/12** (2013.01); **C07D 409/12** (2013.01)

Citation (search report)
See references of WO 9849145A1

Cited by
US10870660B2; US11345716B2; US11897899B2

Designated contracting state (EPC)
BE CH DE ES FR GB IT LI NL

DOCDB simple family (publication)
WO 9849145 A1 19981105; CA 2288308 A1 19981105; EP 0981516 A1 20000301; GB 9708694 D0 19970618; JP 2001522366 A 20011113

DOCDB simple family (application)
EP 9802581 W 19980427; CA 2288308 A 19980427; EP 98929278 A 19980427; GB 9708694 A 19970430; JP 54662098 A 19980427